Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting

Area of Science:

• Biotechnology
• Nanomedicine
• Gene Therapy

Background:

• Systemic gene therapy requires non-toxic vectors with high transfection efficiency.
• Lipid nanocapsules (LNCs) offer a promising platform for gene delivery.
• Poly(ethylene glycol) (PEG)ylation improves stability but can hinder cellular uptake.

Purpose of the Study:

• To develop stable, targeted nanocarriers for systemic gene delivery.
• To enhance the transfection efficiency of DNA-loaded LNCs in hepatocytes.
• To investigate the role of galactose targeting in overcoming PEG shielding.

Main Methods:

• DNA was encapsulated into DOTAP/DOPE lipid nanocapsules (LNCs).
• LNCs were PEGylated using DSPE-mPEG(2000) or F108, with some functionalized with galactose.
• Transfection efficiency was evaluated in primary hepatocytes, measuring luciferase expression.

Main Results:

• DNA LNCs demonstrated transfection efficiency comparable to DOTAP/DOPE lipoplexes.
• PEGylation without targeting ligands reduced transfection efficiency.
• Galactosylated F108-coated DNA LNCs showed an 18-fold increase in luciferase expression compared to non-galactosylated LNCs.

Conclusions:

• Galactose-functionalized PEGylated LNCs enhance targeted gene delivery to hepatocytes.
• Active targeting can overcome the barrier effect of PEGylation in nanocarriers.
• This strategy holds potential for improving systemic gene therapy efficacy.